Toronto, Canada

Nathan John Bryson

 

 

Average Co-Inventor Count = 1.0

ph-index = 1


Loading Chart...
Loading Chart...

Title: Nathan John Bryson: Innovator in Sublingual Drug Formulations

Introduction

Nathan John Bryson is an inventor based in Toronto, Canada. He has made significant contributions to the field of pharmaceuticals, particularly in the development of sublingual drug formulations. Although he currently holds no patents, his work has the potential to impact the treatment of various medical conditions.

Latest Patents

Bryson's latest patents include innovative formulations aimed at treating Parkinson's disease and related disorders. One notable invention is the "Sublingual Films Comprising Apomorphine And An Organic Base," which features sublingual film formulations comprising apomorphine hydrochloride and pyridoxine. This invention was designed to provide effective treatment methods for Parkinson's disease and restless leg syndrome. Another significant patent is "Sublingual Apomorphine," which includes sublingual formulations of apomorphine and apomorphine prodrugs, targeting Parkinson's disease, sexual dysfunction, and depressive disorders.

Career Highlights

Throughout his career, Nathan John Bryson has worked with prominent companies in the pharmaceutical industry. He has been associated with Sunovion Pharmaceuticals Inc. and Cynapsus Therapeutics, Inc., where he contributed to the development of innovative drug delivery systems. His expertise in sublingual formulations has positioned him as a valuable asset in the field.

Collaborations

Bryson has collaborated with notable professionals in the industry, including Anthony John Giovinazzo and Scott David Barnhart. These collaborations have likely enhanced his research and development efforts, leading to advancements in pharmaceutical formulations.

Conclusion

Nathan John Bryson is a dedicated inventor whose work in sublingual drug formulations holds promise for improving treatment options for various medical conditions. His contributions to the pharmaceutical industry reflect his commitment to innovation and patient care.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…